Q-omics provides the consensus-scored RPL10A profile across patient tissues and cancer cell-line models. RPL10A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL10A is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, RPL10A protein abundance shows 29,905 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where RPL10A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL10A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL10A survival associations across molecular data types. RPL10A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL10A RNA expression–survival associations across cancer types. High RPL10A expression shows unfavorable associations in ACC and KIRP, but favorable associations in UVM, MESO, LGG and THYM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL10A RNA expression.
This table summarizes RPL10A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RPL10A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL10A shows lower tumor expression in UCEC and BRCA and higher tumor expression in KIRC, LIHC, COAD and CHOL. The KIRC box plot shows higher RPL10A RNA expression in tumor versus normal tissue (log2 FC = +0.706, t-test p < 0.001).
This table shows molecular features associated with RPL10A in patient tissues and cancer cell lines. In patient samples, RPL10A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL10A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS and LUNG_SCLC.
